NCT05262751View on ClinicalTrials.gov

A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Healthy
Interventions
DRUG

Ofev®

Ofev®

DRUG

Nintedanib formulation 1

Nintedanib formulation 1: Monolithic Nintedanib Modified Release Tablet (MR1) as two Prototypes (MR1-1 and MR1-2).

DRUG

Nintedanib formulation 2

Nintedanib formulation 2: Polyox Nintedanib Modified Release Tablet (MR2) as two Prototypes (MR2-1 and MR2-2).

Trial Locations (1)

NG11 6JS

Quotient Sciences, Nottingham

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05262751 - A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib | Biotech Hunter | Biotech Hunter